Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ondansetron marketed formulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | clinical trial formulation |
| B | ACTIVE_COMPARATOR | non-U.S. marketed formulation |
| Name | Type | Description |
|---|---|---|
| ondansetron clinical trial formulation | DRUG | Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods. |
| ondansetron marketed formulation | DRUG | Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods. |
Inclusion Criteria: * If female, subject is not pregnant or breast-feeding * Subject has been a nonsmoker for at least 6 months * Subject is in good health Exclusion Criteria: * Subject has a history of high blood pressure, asthma, other pulmonary disease, Gastrointestinal (GI) abnormalities/pept...
Ondansetron marketed formulation is used for chemotherapy-induced nausea and vomiting. It is a small molecule being developed by Merck & Company, Inc. for this indication. The drug is currently in Phase 1 clinical development.
Ondansetron marketed formulation is developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical trials to evaluate this small molecule for chemotherapy-induced nausea and vomiting.
Ondansetron marketed formulation is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for chemotherapy-induced nausea and vomiting.
Ondansetron marketed formulation has one completed Phase 1 clinical trial, NCT00972595, titled "Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)". The trial enrolled 45 healthy adult volunteers and was active-controlled.
Ondansetron marketed formulation is a formulation of ondansetron, a medication used for chemotherapy-induced nausea and vomiting. The clinical trial NCT00972595 compared two formulations of ondansetron for bioequivalence in healthy adults.